Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915038 · ClinicalTrials.gov registry record · NA
ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
A NA study of Throat Cancer and HPV Positive Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT06915038: Recruiting NA study of Throat Cancer and HPV Positive Cancer, sponsored by Indiana University.
NCT06915038 is a NA study of Throat Cancer and HPV Positive Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06915038, a NA study of Throat Cancer and HPV Positive Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
Primary Outcome
Time from surgery to first disease recurrence or death from any cause
Conditions Studied
Interventions
- DIAGNOSTIC_TEST NavDx
- RADIATION Adjuvant Radiation 30 Gray
- RADIATION Adjuvant Radiation 40 Gray
Study Locations (2)
Indiana
- IU Health Joe and Shelly Schwarz Cancer Center - Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2028-12 |
| Phase | NA |
What NCT06915038 shows while recruiting
NCT06915038 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Throat Cancer appearing as the primary indexed condition, and to 3 interventions - of which NavDx is the first listed.
NCT06915038 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT06915038 about?
NCT06915038 is a clinical study titled "ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx". This study is a prospective phase II trial, designed to assess the efficacy and feasibility of adjuvant treatment deintensification guided by ctHPVDNA levels for patients with HPV+OPSCC who undergo transoral surgery and neck dissection.
What is the current status of trial NCT06915038?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-06-11. Estimated completion is 2028-12.
What conditions does trial NCT06915038 study?
This clinical trial studies the following conditions: Throat Cancer, HPV Positive Cancer, Tonsil Cancer, Squamous Cell Carcinoma of Oropharynx.
What interventions are being tested in trial NCT06915038?
The interventions under investigation include: NavDx (DIAGNOSTIC_TEST), Adjuvant Radiation 30 Gray (RADIATION), Adjuvant Radiation 40 Gray (RADIATION).
Who is sponsoring clinical trial NCT06915038?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915038 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Throat Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06915038's enrollment target sits among peer trials
120 762nd of 2000 higher than 1,199 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI